Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Centessa Pharmaceuticals (Nasdaq: CNTA) said members of management will participate in multiple investor conferences in Feb–Mar 2026, including Guggenheim Emerging Outlook: Biotech Summit (Feb 12), TD Cowen Health Care (Mar 3), Leerink Global Healthcare (Mar 10) and Jefferies Biotech on the Beach (Mar 11).
According to Centessa, live webcasts and archived recordings will be posted under the Events and Publications tab on the company investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – CNTA
In the Feb 3 session, CNTA gained 1.15%, reflecting a mild positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Event: Guggenheim Emerging Outlook: Biotech Summit
Date: Thursday, February 12, 2026
Fireside Chat: 1:00 PM ET
Event: TD Cowen 46th Annual Health Care Conference
Date: Tuesday, March 3, 2026
Fireside Chat: 3:10 PM ET
Event: Leerink Partners Global Healthcare Conference
Date: Tuesday, March 10, 2026
Fireside Chat: 8:00 AM ET
Event: Jefferies Biotech on the Beach Summit
Date: Wednesday, March 11, 2026
Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness, impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders. For more information, visit www.centessa.com, which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
